Table 1.

Selected phase II trials of weekly Rituximab in CLL/SLL

Reference (Authors / year)	Doses	Prior therapy	Evaluable patients	Response rate (ORR)
McLaughlin et al., 1998	4	Yes	30	13%
Nguyen et al., 1999	4	Yes	10	10%
Winkler et al., 1999	4	Yes	9	11%
Ladetto et al., 2000	4	Yes	7	0%
Huhn et al., 2001	4	Yes	28	25%
Itala et al., 2002	4	Yes	24	35%
Hainsworth et al., 2003	4	No	44	51%
Thomas et al., 2001	8	No	21	90%